






Why focus on improving the efficiency of ESI? Ionization and Transmission Efficiency in an Electrospray Ionization-Mass Spectrometry Interface Jason S. Pagea, Ryan T. Kellya, Keqi Tanga and Richard D. Smith, Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA Journal of the American Society for Mass Spectrometry Volume 18, Issue 9, September 2007, pages 1582-1590 "Ion transmission efficiency, also defined as the fraction of ES current that enters the mass analyzer, has traditionally been limited by losses at the mass spectrometer inlet and at the skimmer [[7] and [21]]. It has been estimated that only about **one out of every 10³–10⁵** analyte ions generated by ESI at atmospheric pressure is actually detected using present instrument designs [[7], [10] and [22]]." Agilent Technologies Our measure is your success. Page 6










































Identification of PPCPs in Water The Use of LC/MS/MS


Pharmaceuticals and Personal Care Products (PPCPs)


refer, in general, to any product used by individuals for personal health or cosmetic reasons or used by agribusiness to enhance growth or health of livestock.


PPCPs comprise a diverse collection of thousands of chemical substances, including prescription and over-the-counter therapeutic drugs, veterinary drugs, fragrances, and cosmetics.















List of Group 1 Compounds EPA 1694: 46 Analytes


Acetaminophen	Codeine	Lincomycin	Sarafloxacin	Sulfanilamide	
Ampicillin	Cotinine	Lomefloxacin	Sulfachloro- pyridazine	Thiabendazole	
Azithromycin	Dehydronifedipine	Miconazole	Sulfadiazine	Trimethoprim	
Caffeine	Digoxigenin	Norfloxacin	Sulfadi-methoxine	Tylosin	
Carbadox	Diltiazem	Ofloxacin	Sulfadiazine	Virginiamycin	
Carbamazepine	1,7-Dimethyl- xanthine	Oxacillin	Sulfadi-methoxine		
Cefotaxime	Diphenhydramine	Oxolinic acid	Sulfamerazine		
Ciprofloxacin	Enrofloxacin Erythromycin	Penicillin G	Sulfamethazine		
Clarithromycin	Flumequine	Penicillin V	Sulfamethizole		
Cloxacillin	Fluoxetine	Roxithromycin	Sulfa-methoxazole		


	ıp <mark>2</mark> , 3 and <mark>4</mark> s: EPA 1694: 19 Analytes			
Anhydrotetracycline	Doxycycline	Minocycline	Triclocarban	
			Triclosan	
			Warfarin	
Chlorotetracycline	4-Epianhydrotetra- cycline	Tetracycline	Albuterol	
		Meclocycline	Cimetidine	
			Metformin	
Demeclocycline	4-Epitetracycline	Gemfibrozil	Ranitidine	
		Ibuprofen		
		Naproxen		
9 32	Our measure is your success.	Agilent Technologies	QQQ talk LCMS US Winte	

List of Labeled Internal Standards

13C-15N- Acetaminophen	13C2-Erythromycin	13C6- Sulfamethazine	13C3-Trimethoprim
13C3-Atrazine	Fluoxetine-d6	13C6- Sulfamethoxazole	Warfarin-d5
13C3-Caffeine	Gemfibrozil-d6	13C6-2,4,5-Tricloro- phenoxyacetic acid	Carbamazepine-d10 (Extra compound, not EPA list)
13C3-15N-Cipro- floxacin	13C3-Ibuprofen	13C6-Triclocarban	
Cotinine-d3	13C-Naproxen-d3	13C12-Triclosan	









MassHunter Optimizer Automated MRM Method Development Software Traditional MS/MS method development: • Manual optimization of even three parameters, for dozens of compounds => MANY Days to WEEKS of tedious, interactive work

WITH Optimizer:

Page 39

Optimization can be fully automated for multiple compounds
 > One or a few DAYS of unattended work!

Compound-specific optimization for MRM experiments


- · Selection and optimization of precursor and product ions
- Supports optimization with multiple methods (e.g. pos then neg)
- Creation of a compound database with optimized parameters for re-use


Our measure is your success. Agilent Technologies


Winter 2009


MassHunter Optimizer Advantages over previous solutions Utmost flexibility via support of all common optimization modes: Manual infusion (syringe pump) Automatic infusion (via loop injection at lower flows) Flow injection analysis without column (FIA) Analysis with column (multiple compounds per run) Optimization WITH column for highest success: Infusion or FIA can result in 20% of cmpds not optimizing Optimizer includes analysis WITH column using fast LC.


Version 2, early 2009: Automatic creation of LC/MS method for large numbers of compounds from Compound Database, using "Scheduled MRM"

















Masshunter Optimiz	zer						<u>- 🗆 ×</u>
😑 Load Project 🔡 S	Save Project 🔣 Sav	eAs Project		🚆 🚺 Start	Optimization 🏠 Io	on Breakdown Profile	
Import From DataB	ase 💿 Import From	n Excel 💿 Expo	rt To Excel	-			
Compound Setup Pre	cursor Ion Selection	Product Ion Selec	tion Distinizer	Setun			
· · ·							
Show results summa	04						
Compound Name	Method	Precursor Ion	Fragmentor	Product Ion	Collision Energy	Abundance	
•				575.88	8	10928	
UCA sectida PVP	D:\MassHunter\m	E47.22	90	589.34	18	18576	
HSA peptide KVP	D:\MassHunter\m	047.32	30	740.43	12	4931	
				900.5	16	3453	
				852.35	22	963	
	N N N N		90	1082.42	24	1253	
HSA peptide AAF	D:\MassHunter\m 6	686.29		1246.12	30	85	
				1339.48	6	18	
	D:\MassHunter\m 6	671.82	90	1041.49	20	6031	
				1172.17	18	3581	
HSA peptide AVM				1202.6	32	10	
				1234.01	32	17	
		464.25	00	488.31	14	4159	
IISA peptide YLY	D:\Messi lunter\m			651.33	12	31063	
				651.98	12	31063	
				764.49	14	2815	
	A peptide LVN D:\MassHunter\m	575.31 !		595.31	18	7911	
UCA analida D.M.			90	694.37	16	6176	
HSA peptide LVN				937.41	16	22612	
				1120.1	24	110	
roject Name : HSA5pe	ptides-1pm] Optimiz	er Status : Ready		Current	Record	All Records	

